<DOC>
	<DOCNO>NCT00007839</DOCNO>
	<brief_summary>RATIONALE : Biological therapy beta alethine use different way stimulate immune system stop cancer cell grow . PURPOSE : Phase I/II trial study effectiveness beta alethine treat patient low-grade lymphoma .</brief_summary>
	<brief_title>Beta Alethine Treating Patients With Low-Grade Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor effect low-dose beta-alethine patient low grade B-cell lymphoma . - Assess effect regimen delayed-type hypersensitivity patient . - Assess safety regimen patient population . OUTLINE : This multicenter study . Patients receive low-dose beta-alethine subcutaneously every 2 week total 6 dos absence unacceptable toxicity . Patients evidence tumor progression may receive additional course therapy . Patients follow 2 week last dose minimum 30 day withdraw due adverse event . PROJECTED ACCRUAL : Approximately 13-37 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cysteamine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm low grade Bcell lymphoma Measurable residual disease maximal response prior chemotherapy OR Indolent disease yet require therapy No congenital immunodeficiency associate lymphoma No primary lymphoma brain No active brain involvement leptomeningeal disease NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % Life expectancy : At least 4 month Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 2.0 mg/dL SGOT/SGPT great 2.5 time upper limit normal ( ULN ) ( great 5 time ULN liver metastasis present ) Renal : Creatinine great 2.0 mg/dL Calculated creatinine clearance least 60 mL/min Cardiovascular : No uncontrolled angina , heart failure , arrhythmia No acute change EKG Other : Not pregnant nursing Fertile patient must use effective contraception HIV negative No AIDS Adequate nutritional status ( total protein least 60.0 g/L ) No active bacterial infection ( e.g. , abscess fistula ) No nonmalignant disease would preclude study No history alcoholism , drug addiction , psychotic disorder would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Prior bone marrow transplantation allow At least 4 week since prior immunotherapy cytokine Chemotherapy : See Disease Characteristics Prior intensive chemotherapy stem cell support allow At least 4 week since prior chemotherapy ( 6 week nitrosoureas , mitomycin , high dose carboplatin ) Endocrine therapy : No concurrent corticosteroid Radiotherapy : At least 4 week since prior radiotherapy 25 % bone marrow Surgery : Recovered prior surgery No prior solid organ transplantation Other : No concurrent antiinflammatory agent include aspirin , counter prescription nonsteroidal antiinflammatory drug No concurrent immunosuppressive agent No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>